April 7, 2026
Allucent Expands Strategic Leadership to Advance Centers of Expertise and Fortify Specialty CRO Position
Learn More
March 30, 2026
Quantum BioPharma Signs Binding Letter of Intent with Allucent to Conduct Phase 2 Clinical Trial in Multiple Sclerosis
Learn More
September 3, 2025
Allucent Appoints New COO, CCO & CIO
Learn More
June 24, 2025
Allucent & Double Bond Pharma Unite to Advance Glioblastoma Trial
Learn More
July 23, 2024
Allucent Names Paula Brown Stafford as CEO Industry Veteran to Lead Next Phase of Global CRO’s Expansion
Learn More
July 9, 2024
Allucent Awarded 5-Year BARDA Agreement Aimed at Enhancing and Accelerating Decentralized Clinical Trials for Medical Countermeasure Development
Learn More
May 15, 2024
Allucent Receives BARDA-Funded Project NextGen Award to Support a COVID-19 Vaccine Decentralized Clinical Trial
Learn More
May 3, 2024
Allucent Recognized with Two CRO Leadership Awards
Learn More
February 20, 2024
Investments Report with Dr. Mark A. Goldberg
Learn More
August 28, 2023
Allucent Awarded BARDA Contract to Support Acceleration of Next-Generation COVID-19 Booster Vaccines
Learn More
- 1
- 2
- 3
- Next page
- » Last page